Determining Line of Therapy from Real-World Data in Non-Small Cell Lung Cancer
Grady, C. B.; Hwang, W.-T.; Reuss, J. E.; Iams, W.; Cass, A.; Liu, G.; Patel, D.; Liu, S. V.; Bravo Montenegro, G. L.; Patel, T.; Nieva, J. J.; Herrmann, A.; Marrone, K. A.; Lam, V. K.; Schwartzman, W.; Dowell, J.; Villaruz, L. C.; Miller, K. L.; Weiss, J.; Sun, F.; Velcheti, V.; Camidge, D. R.; Aggarwal, C.; Sun, L.; Marmarelis, M. E.
Show abstract
IntroductionDetermining lines of therapy (LOT) using real-world data is crucial to inform clinical decisions and support clinical research. Existing rules for determining LOT in patients with metastatic non-small cell lung cancer (mNSCLC) do not incorporate the growing number of targeted therapies used in treatment today. Therefore, we propose rules for determining LOT from real-world data of patients with mNSCLC treated with targeted therapies. MethodsLOT rules were developed through expert consensus using a real-world cohort of 550 patients with ALK+ or ROS1+ mNSCLC in the multi-institutional, electronic medical record-based Academic Thoracic Oncology Medical Investigators Consortiums (ATOMIC) Driver Mutation Registry. Rules were subsequently modified based on a review of appropriate LOT determination. These resulting rules were then applied to an independent cohort of patients with EGFR+ mNSCLC to illustrate their use. ResultsSix rules for determining LOTs were developed. Among 1133 patients with EGFR mutations and mNSCLC, a total of 3168 regimens were recorded with a median of 2 regimens per patient (IQR, 1-4; range, 1-13). After applying our rules, there were 2834 total LOTs with a median of 2 LOTs per patient (IQR, 1-3; range, 1-11). Rules 1-3 kept 11% of regimen changes from advancing the LOT. When compared to previously published rules, LOT assignments differed 5.7% of the time, mostly in LOTs with targeted therapy. ConclusionThese rules provide an updated framework to evaluate current treatment patterns, accounting for the increased use of targeted therapies in patients with mNSCLC and promote standardization of methods for determining LOT from real-world data. Key PointsO_LIUse of targeted therapy to treat patients with mNSCLC is growing C_LIO_LIDetermining lines of therapy from real-world data is crucial for clinical research C_LIO_LIOur rules aim to advance the line of therapy to reflect changes in clinical status C_LIO_LIUsing these rules can lead to better method harmonization in mNSCLC research C_LI
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Towards Predicting 30-Day Readmission among Oncology Patients: Identifying Timely and Actionable Risk Factors 92%
- Large language models to help appeal denied radiotherapy services 92%
- NCT Precision Oncology Thesaurus Drugs – a Curated Database for Drugs, Drug Classes, and Drug Targets in Precision Cancer Medicine 90%
Similar papers in this journal
- An Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in Oncology 92%
- Clinical activity of Mitogen-Activated Protein Kinase (MAPK) inhibitors in patients with MAP2K1 (MEK1)-mutated metastatic cancers 91%
- Clinical activity of MAPK targeted therapies in patients with non-V600 BRAF mutant tumors 91%
Similar papers in this journal
- COVID-19 Outcomes in Patients with Cancer: Findings from the University of California Health System Database 92%
- Can Large Language Models Aid Caregivers of Pediatric Cancer Patients in Information Seeking? A Cross-Sectional Investigation 90%
- Added-value of whole exome and RNA Sequencing in advanced and refractory cancer patients with no molecular-based treatment recommendation based on a 90-gene panel 90%
Similar papers in this journal
- Missing data in the medical record for oncology patients: prevalence and association with outcomes 93%
- Low adherence to existing model reporting guidelines by commonly used clinical prediction models 89%
- A comprehensive systematic review and meta-analysis of the global data involving 61,532 cancer patients with SARS-CoV-2 infection 88%
Similar papers in this journal
- Cost-effectiveness of real-world administration of chemotherapy and add-on Viscum album L. therapy compared to chemotherapy alone in the treatment of stage IV NSCLC patients 90%
- Classification performance bias between training and test sets in a limited mammography dataset 90%
- Efficacy and Cost of High-Frequency IGRT in Elderly Stage III Non-Small-Cell Lung Cancer Patients 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.